19353-97-0

Basic information

• Product Name: 2-methoxyisonicotinohydrazide
• Synonyms: 2-methoxyisonicotinohydrazide
• CAS NO: 19353-97-0
• Molecular Formula: C₇H₉N₃O₂
• Molecular Weight: 167.17
• Mol File: 19353-97-0.mol
• Article Data: 8

Chemical Properties

• Melting Point: 135-137°
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.245g/cm³
• Refractive Index: 1.562
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-methoxyisonicotinohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methoxyisonicotinohydrazide(19353-97-0)
• EPA Substance Registry System: 2-methoxyisonicotinohydrazide(19353-97-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 19353-97-0(Hazardous Substances Data)

Usage

General Description

2-methoxyisonicotinohydrazide is a chemical compound with the molecular formula C7H8N4O2. It is a derivative of isoniazid, an anti-tuberculosis medication, and is known for its potential as an anti-tubercular agent. The methoxy group in its structure contributes to its improved solubility and bioavailability compared to isoniazid. 2-methoxyisonicotinohydrazide is being investigated for its efficacy in combating drug-resistant strains of tuberculosis and has shown promising results in initial studies. It is believed to inhibit the growth of Mycobacterium tuberculosis, the bacterium responsible for causing tuberculosis, and has the potential to be developed into a new treatment for this infectious disease. Further research and clinical trials are needed to fully understand and harness the therapeutic properties of 2-methoxyisonicotinohydrazide.

InChI:InChI=1/C7H9N3O2/c1-12-6-4-5(2-3-9-6)7(11)10-8/h2-4H,8H2,1H3,(H,10,11)

Upstream product

• 105596-63-2 2-methoxy-isonicotinic acid 
• 61832-07-3 2-chloro-6-methoxyisonicotinohydrazide 
• 42521-10-8 2-chloro-6-methoxyisonicotinic acid methyl ester 
• 42521-09-5 methyl 2,6-dichloroisonicotinate 
• 58481-11-1 methyl 2-chloroisonicotinate 
• 26156-51-4 methyl 2-methoxyisonicotinate 

Downstream Products

• 1018680-68-6 4-(5-{1-[5-(3-chloro-phenyl)-isoxazol-3-yl]-ethoxy}-4-methyl-4H-[1,2,4]triazol-3-yl)-1H-pyridin-2-one 
• 1018681-00-9 2-benzyloxy-4-(5-methanesulfonyl-4-methyl-4H-[1,2,4]triazol-3-yl)-pyridine 
• 1380672-05-8 4-(4-(2-chlorophenyl)-5-((E)-2-(5-(2-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl)vinyl)-4H-1,2,4-triazol-3-yl)pyrimidine 
• 1380671-99-7 4-(5-((E)-2-(5-(2,4-dichlorophenyl)-4-(2-chlorophenyl)-4H-1,2,4-triazo-1-3-yl)vinyl)-1,3,4-oxadiazol-2-yl)-2-methoxypyridine 
• 1380672-04-7 2-(4-(2-chlorophenyl)-5-((E)-2-(5-(2-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl)vinyl)-4H-1,2,4-triazol-3-yl)-5-ethoxypyridine 
• 1380672-03-6 4-(5-((E)-2-(4-(2-chlorophenyl)-5-(3-methyl-1,2,4-oxadiazol-5-yl)-4H-1,2,4-triazol-3-yl)vinyl)-1,3,4-oxadiazol-2-yl)-2-methoxypyridine 
• 1380672-02-5 5-chloro-2-(4-(2-chlorophenyl)-5-((E)-2-(5-(2-methoxypyridin-4-yl)-1,3,4-oxadiazol-2-yl)vinyl)-4H-1,2,4-triazol-3-yl)pyridine 

Relevant articles and documents

Surveying heterocycles as amide bioisosteres within a series of mGlu7 NAMs: Discovery of VU6019278

This letter describes a diversity-oriented library approach to rapidly assess diverse heterocycles as bioisosteric replacements for a metabolically labile amide moiety within a series of mGlu7 negative allosteric modulators (NAMs). SAR rapidly

Design, synthesis, and pharmacological and pharmacokinetic evaluation of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives as xanthine oxidoreductase inhibitors

In an effort to find a potent xanthine oxidoreductase (XO) inhibitor, we discovered the best compound 2-[2-(2-methoxy-ethoxy)-ethoxy]-5-[5-(2-methyl-pyridin-4-yl)-1H-[1,2,4]triazol-3-yl]-benzonitrile 28. Here, we describe the following: (1) the design, synthesis, and structure-activity relationship of a series of 3-phenyl-5-pyridyl-1,2,4-triazole derivatives by in vitro studies of XO inhibitory activity in bovine milk and in vivo studies of serum uric acid (UA) reductive activity in rats, (2) a drug interaction study by a cytochrome P450 3A4 (CYP3A4) assay, and (3) a pharmacokinetic (PK) study. Compound 28 exhibits potent XO inhibitory activity, serum UA-lowering activity in rats, weak CYP3A4 inhibitory activity, and moderate PK profile.

MGLUR5 MODULATORS II

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.